)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Astria Therapeutics (ATXS) investor relations material
Astria Therapeutics Corporate Presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate Presentation summary17 Sep, 2025
Strategic vision and pipeline
Focus on developing therapies for hereditary angioedema (HAE) and atopic dermatitis (AD) using half-life extended monoclonal antibodies targeting plasma kallikrein and OX40, respectively.
Pipeline includes navenibart for HAE and STAR-0310 for AD, both advancing through clinical development with multiple upcoming milestones.
Navenibart aims to offer Q3M (every 3 months) and Q6M (every 6 months) dosing options to improve patient convenience and market adoption.
STAR-0310 is positioned as a potential best-in-class OX40 therapy with broad immunomodulatory effects and a long half-life.
Vision to become a leading allergy and immunology company by delivering life-changing therapies.
Clinical development and efficacy data
Navenibart demonstrated 91-95% attack rate reduction in Phase 1b/2 trials, with consistent efficacy and favorable safety in long-term follow-up.
Phase 3 ALPHA-ORBIT and ORBIT-EXPANSE trials are designed to support global registration, with topline data expected in early 2027.
STAR-0310 Phase 1a data show broad and durable suppression of Type 1, 2, and 3 inflammation, with no serious adverse events or dose-limiting side effects.
STAR-0310 exhibits a best-in-class 68-day half-life, supporting potential for every-six-month dosing.
Both programs have shown rapid enrollment and strong engagement from patient communities.
Market opportunity and commercial strategy
HAE market projected to grow from $3.2B in 2024 to $5.4B by 2030, driven by earlier diagnosis and improved therapies.
Navenibart's flexible dosing is anticipated to increase market share, with significant interest from both new and switching patients.
AD market expected to reach $22B in the US by 2030, with large opportunities for therapies targeting inadequately controlled patients.
STAR-0310 aims to capture share from both current standard-of-care and patients not controlled by existing biologics.
Commercial strategy leverages differentiated efficacy, safety, and dosing convenience to drive adoption.
Market adoption impact of Q6M navenibart?
STAR-0310's safety profile vs. rocatinlimab?
STAR-0310's strategy for AD patients on IL-13/4?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Astria Therapeutics earnings date
Q3 202512 Nov, 2025
Next Astria Therapeutics earnings date
Q3 202512 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Astria Therapeutics Inc., formerly known as Catabasis Pharmaceuticals, Inc., is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics for rare and niche allergic and immunological diseases. The company's lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein. Astria Therapeutics is headquartered in Boston, Massachusetts, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage